X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients, by leveraging Caris' proprietary ADAPT Biotargeting platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Recipient: Caris Life Sciences
Deal Size: $1,400.0 million Upfront Cash: Undisclosed
Deal Type: Partnership April 04, 2024
Details:
The collaboration aims to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline using its proprietary TORPEDO® platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: C4 Therapeutics
Deal Size: $756.0 million Upfront Cash: $16.0 million
Deal Type: Collaboration March 04, 2024
Details:
Efti (eftilagimod alpha) a soluble LAG-3 protein and MHC Class II agonist is being evaluated in combination with Bavencio (avelumab) under phase 1 clinical trials forthe treatment of patients with metastatic urothelial carcinoma.
Lead Product(s): Eftilagimod Alpha,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Immutep
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
Under the agreement, Merck will receive an exclusive license to RGX-202 (ompenaclid), currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer, outside of the United States and an option to co-develop and co-promote ompenaclid in the US.
Lead Product(s): RGX-202,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: RGX-202
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Inspirna
Deal Size: Undisclosed Upfront Cash: $45.0 million
Deal Type: Licensing Agreement January 04, 2024
Details:
Under the agreement, Merck will supply ITM with its first-in-class folate precursors for radiolabeling, which ITM will use to advance the clinical and potential future commercial development of its folate receptor-targeting radiopharmaceutical pipeline, including ITM-52.
Lead Product(s): ITM-52
Therapeutic Area: Oncology Product Name: ITM-52
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Isotope Technologies Munich
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2023
Details:
M2951 (evobrutinib) is a BTK inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of relapsing multiple sclerosis via oral tablet.
Lead Product(s): Evobrutinib
Therapeutic Area: Neurology Product Name: M2951
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
Under the agreement, Merck will receive an exclusive license to commercialize ABSK021 (pimicotinib), an oral, highly selective and potent small-molecule antagonist of colony stimulating factor-1 receptor, currently in Phase III for tenosynovial giant cell tumor.
Lead Product(s): Pimicotinib
Therapeutic Area: Oncology Product Name: ABSK021
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Abbisko Therapeutics
Deal Size: Undisclosed Upfront Cash: $70.0 million
Deal Type: Licensing Agreement December 04, 2023
Details:
Under the agreement, Merck will develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167 and Claudin-18.2 antibody-drug conjugate (ADC) SHR-A1904.
Lead Product(s): HRS-1167
Therapeutic Area: Oncology Product Name: HRS-1167
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Merck KGaA
Deal Size: $1,482.0 million Upfront Cash: $169.3 million
Deal Type: Licensing Agreement October 30, 2023
Details:
Under the collaboration, Merck will assess Quris-AI platform’s ability to effectively identify liver toxicity risks in a selection of drug candidates.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: Quris
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration September 28, 2023
Details:
Uner the collaboration, Merck will leverage Exscientia’s AI-driven precision drug design and discovery capabilities in oncology and neuroinflammation. Three potential first-in-class or best-in-class targets have been identified as the initial focus of the partnership.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Exscientia
Deal Size: $694.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration September 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
